ADVFN Logo ADVFN
Donnée du Marché
Actualité
Outils
Donnée du Marché
Discover

Hot Features

Follow Feed

Rester connecter avec les traders et investisseurs dans notre communauté Follow Feed.

Flux des Options

Explorez des données complètes sur les options et utilisez les filtres avancés avec Options Flow.

Moniteur

Organisez et surveillez vos d'actions et actifs avec le Moniteur.
Se connecter Premium IconPremium Help Menu
CAC 40
7 628,80
0,76%
Dow Jones
38 809,93
0,08%
DAX
18 131,97
0,32%
Brent Oil
84,365
0,55%
Bitcoin
64 596,01
-2,84%
Registration Strip Icon for monitor Surveillez plusieurs cotations en temps réel des principales bourses, telles que Euronext Paris, NASDAQ, NYSE, AMEX, Bovespa et plus encore.
S'inscrire
  1. Accueil
  2. Investir
  3. Actions
  4. Etats-Unis
  5. NASDAQ
  6. Axovant Gene Therapies Ltd (AXGT)

  7. Axovant Gene Therapies Ltd (AXGT) Actualités

AXGT

Axovant Gene Therapies (AXGT)

Axovant Gene Therapies Ltd
De:
Trier par:
 Showing the most relevant articles for your search:NASDAQ:AXGT
DateHeureSourceTitreSymboleSociété
25/04/202322h05Edgar (US Regulatory)Termination of Registration of a Class of Security Under Section 12(g) (15-12g)NASDAQ:AXGTAxovant Gene Therapies Ltd
17/04/202322h17Edgar (US Regulatory)Post-effective Amendment to Registration Statement (pos Am)NASDAQ:AXGTAxovant Gene Therapies Ltd
17/04/202322h14Edgar (US Regulatory)Post-effective Amendment to an S-8 Filing (s-8 Pos)NASDAQ:AXGTAxovant Gene Therapies Ltd
12/04/202314h52Edgar (US Regulatory)Notification Filed by National Security Exchange to Report the Removal From Listing and Registration of Matured, Redeemed or Retired Securities Initial Filing Amendments (25-nse)NASDAQ:AXGTAxovant Gene Therapies Ltd
06/04/202322h08Edgar (US Regulatory)Notification Filed by a National Securities Exchange to Report the Removal From Listing and Registration of Matured , Redeemed or Retired Securities (25)NASDAQ:AXGTAxovant Gene Therapies Ltd
06/04/202322h07Edgar (US Regulatory)Current Report Filing (8-k)NASDAQ:AXGTAxovant Gene Therapies Ltd
17/03/202311h03Edgar (US Regulatory)Additional Proxy Soliciting Materials (definitive) (defa14a)NASDAQ:AXGTAxovant Gene Therapies Ltd
21/02/202322h06Edgar (US Regulatory)Proxy Statement - Merger or Acquisition (definitive) (defm14a)NASDAQ:AXGTAxovant Gene Therapies Ltd
14/02/202312h47Edgar (US Regulatory)Quarterly Report (10-q)NASDAQ:AXGTAxovant Gene Therapies Ltd
13/02/202314h53Edgar (US Regulatory)Amended Statement of Ownership (sc 13g/a)NASDAQ:AXGTAxovant Gene Therapies Ltd
10/02/202322h01Edgar (US Regulatory)Statement of Ownership (sc 13g)NASDAQ:AXGTAxovant Gene Therapies Ltd
09/02/202312h01Edgar (US Regulatory)Proxy Statement - Merger or Acquisition (preliminary) (prem14a)NASDAQ:AXGTAxovant Gene Therapies Ltd
14/06/202213h02Edgar (US Regulatory)Annual Report (10-k)NASDAQ:AXGTAxovant Gene Therapies Ltd
10/02/202223h08Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:AXGTAxovant Gene Therapies Ltd
06/10/202123h19Edgar (US Regulatory)Securities Registration: Employee Benefit Plan (s-8)NASDAQ:AXGTAxovant Gene Therapies Ltd
06/08/202122h15Edgar (US Regulatory)Proxy Statement (definitive) (def 14a)NASDAQ:AXGTAxovant Gene Therapies Ltd
16/12/202013h00Edgar (US Regulatory)Prospectus Filed Pursuant to Rule 424(b)(5) (424b5)NASDAQ:AXGTAxovant Gene Therapies Ltd
02/12/202013h00GlobeNewswire Inc.Sio Gene Therapies Announces First Patient Dosed in High-Dose Cohort of AXO-AAV-GM1 Clinical Trial in Patients with GM1 Gangl...NASDAQ:AXGTAxovant Gene Therapies Ltd
20/11/202012h04Edgar (US Regulatory)Notice of Effectiveness (effect)NASDAQ:AXGTAxovant Gene Therapies Ltd
19/11/202014h00GlobeNewswire Inc.Sio Gene Therapies Appoints Gene Therapy Pioneer Guangping Gao, Ph.D., as Chief AAV Scientific AdvisorNASDAQ:AXGTAxovant Gene Therapies Ltd
13/11/202013h06Edgar (US Regulatory)Registration of Securities of Successor Issuers (8-k12g3)NASDAQ:AXGTAxovant Gene Therapies Ltd
13/11/202013h00GlobeNewswire Inc.Sio Gene Therapies Announces Corporate Updates and Financial Results for Second Fiscal Quarter Ended September 30, 2020NASDAQ:AXGTAxovant Gene Therapies Ltd
10/11/202023h11Edgar (US Regulatory)Registration Statement for Securities to Be Issued in Business Combination Transactions (s-4/a)NASDAQ:AXGTAxovant Gene Therapies Ltd
10/11/202013h00GlobeNewswire Inc.Axovant Gene Therapies Announces Name Change to Sio Gene TherapiesNASDAQ:AXGTAxovant Gene Therapies Ltd
09/11/202013h00GlobeNewswire Inc.Axovant Gene Therapies Announces FDA Clearance of IND for AXO-AAV-GM2 Gene Therapy in Tay-Sachs and Sandhoff DiseasesNASDAQ:AXGTAxovant Gene Therapies Ltd
29/10/202021h01GlobeNewswire Inc.Axovant Gene Therapies to Present AXO-Lenti-PD Program Update During Virtual Parkinson’s Disease R&D Day on October 30, 202...NASDAQ:AXGTAxovant Gene Therapies Ltd
22/10/202013h00GlobeNewswire Inc.Axovant Gene Therapies to Host Virtual Parkinson’s Disease R&D Day on October 30, 2020NASDAQ:AXGTAxovant Gene Therapies Ltd
13/10/202013h00GlobeNewswire Inc.Axovant Gene Therapies Receives Rare Pediatric Disease Designation for AXO-AAV-GM2 for Tay-Sachs and Sandhoff DiseaseNASDAQ:AXGTAxovant Gene Therapies Ltd
09/10/202013h00GlobeNewswire Inc.Axovant Gene Therapies Receives Rare Pediatric Disease Designation for AXO-AAV-GM1 for GM1 GangliosidosisNASDAQ:AXGTAxovant Gene Therapies Ltd
08/10/202013h00GlobeNewswire Inc.Axovant Gene Therapies Strengthens Board of Directors and Announces New Chief Commercial OfficerNASDAQ:AXGTAxovant Gene Therapies Ltd
 Showing the most relevant articles for your search:NASDAQ:AXGT

Dernières Valeurs Consultées

NYSE
KO
Coca Cola
EU
BEL20
Bel 20
EU
ML
Michelin
SPI
SP500
S&P 500
USI
USTECH100
US Tech 100
NYSE
DIS
Walt Disney
EU
EN
Bouygues
EU
HO
Thales
COIN
BTCUSD
Bitcoin
NASDAQ
MSFT
Microsoft
EU
BNP
BNP Paribas
NASDAQ
GOOGL
Alphabet
EU
PX1
CAC 40
NYSE
MRK
Merck
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

France
Société
Entreprise
Popular
Obtenir l'application
App Store
Google Play

Assistance: support@advfn.fr

En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales

© 2024 ADVFN PLC - Tous droits réservés